{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:33:53Z","timestamp":1791232433379,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.clml.2012.08.004","type":"journal-article","created":{"date-parts":[[2012,11,3]],"date-time":"2012-11-03T06:31:11Z","timestamp":1351924271000},"page":"62-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Relocalization of KIT D816V to Cell Surface After Dasatinib Treatment: Potential Clinical Implications"],"prefix":"10.1016","volume":"13","author":[{"given":"Houcine","family":"Bougherara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Georgin-Lavialle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gandhi","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Lhermitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Auclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Arock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Alix","family":"Poul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2012.08.004_bib1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.clml.2012.08.004_bib2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2012.08.004_bib3","doi-asserted-by":"crossref","first-page":"e1906","DOI":"10.1371\/journal.pone.0001906","article-title":"Phenotypic and genotypic characteristics of mastocytosis according to the age of onset","volume":"3","author":"Lanternier","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clml.2012.08.004_bib4","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clml.2012.08.004_bib5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0145-2126(01)00050-9","article-title":"Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis","volume":"25","author":"Escribano","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2012.08.004_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cyto.b.10072","article-title":"Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it","volume":"58","author":"Escribano","year":"2004","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.clml.2012.08.004_bib7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.10.020","article-title":"Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes","volume":"125","author":"Teodosio","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clml.2012.08.004_bib8","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/blood-2011-02-335950","article-title":"Blood CD34-c-Kit+ cell rate correlates with aggressive forms of systemic mastocytosis and behaves like a mast cell precursor","volume":"118","author":"Georgin-Lavialle","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.08.004_bib9","first-page":"1115","article-title":"Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant","volume":"1","author":"Frost","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2012.08.004_bib10","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1541-7786.MCR-09-0138","article-title":"The aberrant localization of oncogenic Kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment","volume":"7","author":"Bougherara","year":"2009","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.clml.2012.08.004_bib11","series-title":"Mastocytosis (mast cell disease)","first-page":"291","year":"2001"},{"key":"10.1016\/j.clml.2012.08.004_bib12","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.V91.8.2731.2731_2731_2736","article-title":"Indolent Systemic Mast Cell Disease in Adults: Immunophenotypic Characterization of Bone Marrow Mast Cells and its Diagnostic Implications","volume":"98","author":"Escribano","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.08.004_bib13","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2012.08.004_bib14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.leukres.2008.09.027","article-title":"Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT","volume":"D816V:33","author":"Ustun","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2012.08.004_bib15","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.08.004_bib16","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.08.004_bib17","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1158\/1078-0432.CCR-07-4102","article-title":"KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors","volume":"14","author":"Tabone-Eglinger","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2012.08.004_bib18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.molcel.2009.09.019","article-title":"Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes","volume":"36","author":"Choudhary","year":"2009","journal-title":"Mol Cell"},{"key":"10.1016\/j.clml.2012.08.004_bib19","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1038\/onc.2010.595","article-title":"The constitutive activity of the ALK mutated at positions F1174 or R 1275 Impairs receptor trafficking","volume":"30","author":"Mazot","year":"2011","journal-title":"Oncogene"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012001607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012001607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:23:56Z","timestamp":1761870236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265012001607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S2152265012001607"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2012.08.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relocalization of KIT D816V to Cell Surface After Dasatinib Treatment: Potential Clinical Implications","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2012.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}